Success Stories
Highlights of the PCI news focused on Penn commercialization accomplishments
PCI’s Inyoung Lee Awarded 2025 Howard Bremer Scholarship
This prestigious annual award recognizes and supports students and emerging professionals pursuing careers in technology transfer.
PCI’s Melissa Kelly Wins 2025 Models of Excellence Award
Melissa is the Deputy Managing Director at PCI.
PCI’s 10th Anniversary Recognized by Technical.ly Philly
Technical.ly Philly recognized PCI for its key role in transforming Penn’s research into real-world applications.
GEMMABio and Sahay AI Make Technical.ly Philly’s RealLIST of Up-and-Coming Startups
Technical.ly’s annual RealLIST Startups identifies the top young companies in the Philadelphia region who are on track to continue their momentum.
PCI Hosts Mandela Fellow David Jeng of The Gambia
During his time at PCI, David worked on a wide range of projects and hopes to eventually establish an innovation hub in Africa that will address intellectual property issues for Africans.
Penn’s Boon Loo Talks to Technical.ly Philly about his Experience in Academic Entrepreneurship
Penn Engineering’s Boon Thau Loo, PhD, Senior Associate Dean for Education and Global Initiatives, was featured in Technical.ly Philly for his deep personal experiences with academic entrepreneurship.
President’s Sustainability Prize Winner Shinkei Systems Aims to Upend the Fish-Harvesting Industry
The 2022 President’s Sustainability Prize winner Shinkei Systems was recognized in a recent article by Tech Crunch for its role in changing the seafood industry.
EpiVario Awarded NIH Grant to Advance Research in Treatments for Cocaine Use Disorder
EpiVario is developing neuroepigenetic modulators to treat memory-related addiction and psychiatric disorders.
Interius BioTherapeutics Receives Clearance to Begin Phase 1 Clinical Trial for Its First-in-Class In Vivo CAR Therapeutic for B Cell Malignancies
Interius intends to begin patient enrollment for the trial in the fourth quarter of 2024.
Development of RNA Therapeutics Targets Neurological Diseases
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.